Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
Investing.com -- Avantor, Inc. (NYSE:AVTR) shares fell 3.05% on Friday after the life sciences tools company reported second quarter adjusted earnings that missed analyst expectations, despite slightly exceeding revenue forecasts.
The company reported adjusted earnings per share of $0.24 for the second quarter, falling short of the $0.25 analyst consensus.
Revenue came in at $1.68 billion, marginally above the $1.67 billion estimate, but still representing a 1% decrease compared to the same period last year. On an organic basis, revenue was flat year-over-year.
Avantor’s second quarter net income declined to $64.7 million from $92.9 million in the prior-year period, with net income margin at 3.8%. Adjusted EBITDA was $279.8 million with a margin of 16.6%, while adjusted operating income reached $252.2 million with a 15% margin.
"In the second quarter, we remained focused on driving growth, enhancing operating leverage, and executing with discipline," said Michael Stubblefield, President and Chief Executive Officer, who will be stepping down from his role on August 18.
By segment, Laboratory Solutions reported net sales of $1.12 billion, a 3% decrease (1% decline organically), while Bioscience Production saw net sales increase 3% to $561.3 million (2% growth organically).
The company generated operating cash flow of $154.4 million and free cash flow of $125.4 million during the quarter. Adjusted net leverage stood at 3.2x as of June 30, 2025.
Avantor previously announced that Emmanuel Ligner will succeed Stubblefield as President and CEO effective August 18, 2025.
Stubblefield noted that despite challenges, "Avantor’s resilient business model, diversified portfolio, and long-standing customer relationships, coupled with our focus on operational excellence, position us to navigate near-term challenges and deliver long-term shareholder value."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.